News
-
-
PRESS RELEASE
EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year
Eckert & Ziegler SE reports increased sales and earnings in the first nine months of 2024 compared to previous year. Strong performance indicated by sales of EUR 215.5 million and EBIT of EUR 46.7 million -
-
-
-
-
-
-
-
PRESS RELEASE
Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
Eckert & Ziegler SE partners with Telix Pharmaceuticals for ProstACT GLOBAL Phase III study, serving as European CMO and supplier of Lu-177, aiming to advance prostate cancer treatment